{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:46:10Z","timestamp":1793814370272,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Secondary immunodeficiencies are frequently observed after allo-HSCT. The efficacy of subcutaneous IgG preparations in this population is unknown. A retrospective single-institution study involved 126 adult patients transplanted in 2012\u20132019 for hematological malignancies. Patients were tested every 2\u20133\u00a0weeks for plasma IgG concentration during the 1st year after transplantation and supplemented with facilitated subcutaneous immunoglobulin when they either had IgG concentration\u2009&lt;\u2009500\u00a0mg\/dl or between 500 and 700\u00a0mg\/dl and recurrent infection. The IgG concentration\u2009&lt;\u2009500\u00a0mg\/dL was diagnosed in 41 patients, while 500\u2013700\u00a0mg\/dL in 25 and altogether 53 patients received IgG supplementation. The median number of IgG administrations was 2. The median time to the first IgG administration after allo-HSCT was 4.1\u00a0months, while to the next administration (if more than one was required) 53\u00a0days (prophylactic group) and 32\u00a0days (group with infections). We did not observe any significant toxicity. Two situations were associated with increased probability of meeting criteria for IgG supplementation: diagnosis of either acute lymphoblastic leukemia (ALL) or chronic lymphocytic leukemia (CLL) (83.8% versus 39.3% for other diagnosis,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.000) and the systemic use of corticosteroids (64.2% versus 31.5% for patients without systemic corticosteroids,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.005). Over 40% of the adult recipients may require at least incidental immunoglobulin supplementation during the first year after allo-HSCT. Low IgG concentrations are associated with inferior outcomes. The subcutaneous route of IgG administration appeared to be safe and may allow for long persistence.\n                  <\/jats:p>","DOI":"10.1007\/s00277-021-04649-y","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T16:35:05Z","timestamp":1630686905000},"page":"3007-3016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation\u2014a single-center analysis"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-5041","authenticated-orcid":false,"given":"Ewa","family":"Karakulska-Prystupiuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Dwilewicz-Trojaczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Drozd-Soko\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Kmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Chlebus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Szczypi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Boguradzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Tomaszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"M\u0105dry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Bili\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz W\u0142adys\u0142aw","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies\u0142aw Wiktor","family":"J\u0119drzejczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"8","key":"4649_CR1","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41409-020-0826-4","volume":"55","author":"JR Passweg","year":"2020","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, Dolstra H, Lenkester AC, Mohty M, Montoto S, de Latour RP, Snowden JA, Styczy\u0144ski J, Yakoub-Agha I, Kr\u00f6ger N (2020) European Society for Blood and Marrow Transplantation (EBMT). The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T\u2019s come into focus. Bone Marrow Transplant 55(8):1604\u20131613. https:\/\/doi.org\/10.1038\/s41409-020-0826-4","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4649_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","volume":"55","author":"J Styczy\u0144ski","year":"2020","unstructured":"Styczy\u0144ski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Lyungman P, Averbuch D, de la Camara R, Baldomelo H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kuball J, Lankester A, Montoto S, Nagler A, Snowden JA, Kr\u00f6ger N, Mohty M, Gratwohl A (2020) Infectious Diseases Working Party EBMT. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant 55(1):126\u2013136. https:\/\/doi.org\/10.1038\/s41409-019-0624-z","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4649_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/sj.bmt.1705892","volume":"41","author":"AC Norlin","year":"2008","unstructured":"Norlin AC, Sairafi D, Mattsson J, Ljungman P, Ringd\u00e9n O, Remberger M (2008) Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 41(3):267\u2013273. https:\/\/doi.org\/10.1038\/sj.bmt.1705892","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"4649_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14712598.8.5.583","volume":"8","author":"J Storek","year":"2008","unstructured":"Storek J (2008) Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft. Expert OpinBiolTher 8(5):583\u2013597. https:\/\/doi.org\/10.1517\/14712598.8.5.583","journal-title":"Expert OpinBiolTher"},{"issue":"7","key":"4649_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","volume":"17","author":"J Ogonek","year":"2016","unstructured":"Ogonek J, KraljJuric M, Ghimire S, Varanasi PR, Holler E, Greinix H, Weissinger E (2016) Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 17(7):507. https:\/\/doi.org\/10.3389\/fimmu.2016.00507","journal-title":"Front Immunol"},{"key":"4649_CR6","doi-asserted-by":"publisher","unstructured":"Carreras E, Dufour C, Mohty M, Kroger N 2019 (eds), The EBMT Handbook, eBook, https:\/\/doi.org\/10.1007\/978-3-030-02278-5.","DOI":"10.1007\/978-3-030-02278-5"},{"issue":"11","key":"4649_CR7","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","volume":"10","author":"LR Baden","year":"2012","unstructured":"Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marr KA, Montoya JG, Morris-Engemann A, Pappas PG, Rolston K, Segal B, Seo SK, Swaminathan S, Naganuma M, Shead DA (2012) National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. J NatlComprCancNetw 10(11):1412\u201345. https:\/\/doi.org\/10.6004\/jnccn.2012.0146","journal-title":"J NatlComprCancNetw"},{"key":"4649_CR8","unstructured":"European Medicines Agency, Guidelines on the clinical investigation of human normal immunoglobulin for intravenous administration. 28 June 2018. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-human-normal-immunoglobuin-intravenous-administration-ivig-rev-3_en.pdf"},{"issue":"10","key":"4649_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ, Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group (2009) American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15(10):1143\u2013238. https:\/\/doi.org\/10.1016\/j.bbmt.2009.06.019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"4649_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s10875-017-0469-4","volume":"38","author":"JDM Edgar","year":"2018","unstructured":"Edgar JDM, Richter AG, Huissoon AP, Kumararatne DS, Baxendale HE, Bethune CA, Garcez T, Misbah SA, Sorensen RU, United Kingdom Primary Immunodeficiency Network (UKPIN) Immunoglobulin Decision to Treat Study Group (2018) Prescribing immunoglobulin replacement therapy for patients with non-classical and secondary antibody deficiency: an analysis of the practice of clinical immunologists in the UK and Republic of Ireland. J ClinImmunol 38(2):204\u2013213. https:\/\/doi.org\/10.1007\/s10875-017-0469-4","journal-title":"J ClinImmunol"},{"issue":"9","key":"4649_CR11","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00277-016-2711-1","volume":"95","author":"AJ Ullmann","year":"2016","unstructured":"Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Kr\u00fcger W, Mousset S, Neuburger S, Neumann S, Penack O, Silling G, Vehreschild JJ, Einsele Maschmeyer HG (2016) Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO\/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation). Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol 95(9):1435\u201355. https:\/\/doi.org\/10.1007\/s00277-016-2711-1","journal-title":"Ann Hematol"},{"issue":"4","key":"4649_CR12","doi-asserted-by":"publisher","first-page":"CD006501","DOI":"10.1002\/14651858.CD006501.pub2","volume":"8","author":"P Raanani","year":"2008","unstructured":"Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O (2008) Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev 8(4):CD006501. https:\/\/doi.org\/10.1002\/14651858.CD006501.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"4649_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21(3):389-401.e1. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4649_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, W\u00f6lfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JL, Levine JE (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 22(1):4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"4649_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18(4):295\u2013304. https:\/\/doi.org\/10.1097\/00007890-197410000-00001","journal-title":"Transplantation"},{"issue":"6","key":"4649_CR16","doi-asserted-by":"publisher","first-page":"E200","DOI":"10.1016\/S1473-3099(18)30600-5","volume":"19","author":"C Cordonnier","year":"2019","unstructured":"Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, de Lavallade H, Gallo G, Lehrnbecher T, Engelhard D, Ljungman P, on behalf of the European Conference on Infections in Leukaemia group (2019) Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infect Dis 19(6):E200\u2013E212. https:\/\/doi.org\/10.1016\/S1473-3099(18)30600-5","journal-title":"The Lancet Infect Dis"},{"key":"4649_CR17","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 e-pub: https:\/\/ctep.cancer.gov. Accessed 27 Nov 2017"},{"key":"4649_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2014.28","volume":"49","author":"Y Arai","year":"2014","unstructured":"Arai Y, Yamashita K, Mizugishi K, Kondo T, Kitano T, Hishizawa M, Kadowaki N, Takaori-Kondo A (2014) Risk factors for hypogammaglobulinemia after allo-SCT. Bone Marrow Transplant 49:859\u2013861. https:\/\/doi.org\/10.1038\/bmt.2014.28","journal-title":"Bone Marrow Transplant"},{"key":"4649_CR19","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/bmt.2013.76","volume":"48","author":"H Frangoul","year":"2013","unstructured":"Frangoul H, Min E, Wang W, Chandrasekhar R, Calder C, Evans M, Manes B, Bruce K, Brown V, Ho R, Domm J (2013) Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT. Bone Marrow Transplant 48:1456\u20131459. https:\/\/doi.org\/10.1038\/bmt.2013.76","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"4649_CR20","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.leukres.2015.10.013","volume":"39","author":"F De Angelis","year":"2015","unstructured":"De Angelis F, Tosti ME, Capria S, Russo E, D\u2019Elia GM, Annechini G, Stefanizzi C, Fo\u00e0 R, Pulsoni A (2015) Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. Leuk Res 39(12):1382\u20131388. https:\/\/doi.org\/10.1016\/j.leukres.2015.10.013","journal-title":"Leuk Res"},{"issue":"12","key":"4649_CR21","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.bbmt.2017.08.010","volume":"23","author":"A Forcina","year":"2017","unstructured":"Forcina A, Rancoita PMV, Marcatti M, Greco R, Lupo-Stanghellini MT, Carrabba M, Marasco V, Di Serio C, Bernardi M, Peccatori J, Corti C, Bondanza A, Ciceri F (2017) A new clinicobiological scoring, system for the prediction of infection-related mortality and survival after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 23(12):2151\u20132158. https:\/\/doi.org\/10.1016\/j.bbmt.2017.08.010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"4649_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","volume":"8","author":"SY Patel","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S (2019) The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol 8(10):33. https:\/\/doi.org\/10.3389\/fimmu.2019.00033","journal-title":"Front Immunol"},{"issue":"3S","key":"4649_CR23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"EE Perez","year":"2017","unstructured":"Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, Nelson R, Secord E, Jordan SC, Stiehm ER, Vo AA, Ballow M (2017) Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy ClinImmunol 139(3S):S1\u2013S46. https:\/\/doi.org\/10.1016\/j.jaci.2016.09.023","journal-title":"J Allergy ClinImmunol"},{"issue":"4 Suppl","key":"4649_CR24","doi-asserted-by":"publisher","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"JS Orange","year":"2006","unstructured":"Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C (2006) Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy ClinImmunol 117(4 Suppl):S525-53. https:\/\/doi.org\/10.1016\/j.jaci.2006.01.015","journal-title":"J Allergy ClinImmunol"},{"issue":"2","key":"4649_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.blre.2017.09.003","volume":"32","author":"M Ueda","year":"2018","unstructured":"Ueda M, Berger M, Gale RP, Lazarus HM (2018) Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Rev 32(2):106\u2013115. https:\/\/doi.org\/10.1016\/j.blre.2017.09.003","journal-title":"Blood Rev"},{"issue":"Suppl 5","key":"4649_CR26","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","volume":"26","author":"B Eichhorst","year":"2015","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Mey U (2015) ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v78-84. https:\/\/doi.org\/10.1093\/annonc\/mdv303","journal-title":"Ann Oncol"},{"issue":"3","key":"4649_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cei.12915","volume":"188","author":"S Jolles","year":"2017","unstructured":"Jolles S, Chapel H, Litzman J (2017) When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. ClinExpImmunol 188(3):333\u2013341. https:\/\/doi.org\/10.1111\/cei.12915","journal-title":"ClinExpImmunol"},{"issue":"1","key":"4649_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jac\/dkx324","volume":"73","author":"Cesaro S, Dalianis T, HanssenRinaldo C, Koskenvuo M, Pegoraro A, Einsele H, Cordonnier C, Hirsch HH. ECIL-6 Group","year":"2018","unstructured":"Cesaro S, Dalianis T, HanssenRinaldo C, Koskenvuo M, Pegoraro A, Einsele H, Cordonnier C, Hirsch HH. ECIL-6 Group (2018) ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J AntimicrobChemother 73(1):12\u201321. https:\/\/doi.org\/10.1093\/jac\/dkx324","journal-title":"J AntimicrobChemother"},{"issue":"2","key":"4649_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/ndt\/gfu023","volume":"30","author":"D Sawinski","year":"2015","unstructured":"Sawinski D, Goral S (2015) BK virus infection: an update on diagnosis and treatment. Nephrol Dial Transplant 30(2):209\u2013217. https:\/\/doi.org\/10.1093\/ndt\/gfu023","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"4649_CR30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fimmu.2016.00500","volume":"14","author":"M Reis","year":"2016","unstructured":"Reis M, Ogonek J, Qesari M, Borges NM, Nicholson L, Preu\u00dfner L, Dickinson AM, Wang XN, Weissinger EM, Richter A (2016) Recent developments in cellular immunotherapy for HSCT-associated complications. Front Immunol 14(7):500. https:\/\/doi.org\/10.3389\/fimmu.2016.00500","journal-title":"Front Immunol"},{"issue":"6","key":"4649_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/sj.bmt.1703185","volume":"28","author":"S D'Costa","year":"2001","unstructured":"D\u2019Costa S, Slobod KS, Benaim E, Bowman L, Cunningham J, Holladay M, Howlett N, Srivastava DK, Hurwitz JL (2001) Effect of extended immunosuppressive drug treatment on B cell vs T cell reconstitution in pediatric bone marrow transplant recipients. Bone Marrow Transplant 28(6):573\u2013580. https:\/\/doi.org\/10.1038\/sj.bmt.1703185","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4649_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7326\/0003-4819-139-1-200307010-00007","volume":"139","author":"Cordonnier C, Chevret S, Legrand M, Rafi H, Dh\u00e9din N, Lehmann B, Bassompierre F, Gluckman E. GREFIG Study Group","year":"2003","unstructured":"Cordonnier C, Chevret S, Legrand M, Rafi H, Dh\u00e9din N, Lehmann B, Bassompierre F, Gluckman E. GREFIG Study Group (2003) Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139(1):8\u201318. https:\/\/doi.org\/10.7326\/0003-4819-139-1-200307010-00007","journal-title":"Ann Intern Med"},{"issue":"2","key":"4649_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbmt.2007.10.009","volume":"14","author":"HT Greinix","year":"2008","unstructured":"Greinix HT, Pohlreich D, Kouba M, K\u00f6rm\u00f6czi U, Lohmann I, Feldmann K, Zielinski C, Pickl WF (2008) Elevated numbers of immature\/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant 14(2):208\u2013219. https:\/\/doi.org\/10.1016\/j.bbmt.2007.10.009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"4649_CR34","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1592\/phco.20.15.1175.34592","volume":"20","author":"SY DeRienzo","year":"2000","unstructured":"DeRienzo SY, Chiang KY, O\u2019Neal WM, Godder K, Abhyankar S, Christiansen NP, Bridges KD, Henslee-Downey PJ (2000) Evaluation of the half-life of intravenous human cytomegalovirus immune globulin in patients receiving partially mismatched related donor bone marrow transplantation. Pharmacotherapy 20(10):1175\u20131178. https:\/\/doi.org\/10.1592\/phco.20.15.1175.34592","journal-title":"Pharmacotherapy"},{"issue":"7","key":"4649_CR35","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.21873\/anticanres.12712","volume":"38","author":"M Dimou","year":"2018","unstructured":"Dimou M, Iliakis T, Maltezas D, Bitsani A, Kalyva S, Koudouna A, Kotsanti S, Petsa P, Papaioannou P, Kyrtsonis MC, Panayiotidis P (2018) Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis Anticancer Res 38(7):4187\u20134191. https:\/\/doi.org\/10.21873\/anticanres.12712","journal-title":"A Single-Center Retrospective Analysis Anticancer Res"},{"issue":"4","key":"4649_CR36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","volume":"130","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl H, Leibl W , McCoy B, Empson VG, Gelmont D, Schiff RI, IGSC, 10% with rHuPH20 Study Group (2012) Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy ClinImmunol 130(4):951\u20137.e11. https:\/\/doi.org\/10.1016\/j.jaci.2012.06.021","journal-title":"J Allergy ClinImmunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04649-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T09:04:46Z","timestamp":1636967086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04649-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4649"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04649-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-168088\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"21 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical consent was approved by Medical University of Warsaw, Bioethical Commission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This is a retrospective analysis of anonymous data contained in medical records.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable because there is no identifying information about patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author Wies\u0142aw Wiktor J\u0119drzejczak has received research support from: Roche, Novartis, Celgene, Janssen-Cilag, Takeda, Abbvie and BMS companies. Other authors declare no financial interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}